Home > Insider Trading > Filing (0000950170-24-041841)

Filing Details

Accession Number:: 0000950170-24-041841
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-04-04 16:30:30
Reporting Period:: 2024-04-02

Accepted Time:: 2024-04-04 16:30:30
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1782303	Boundless Bio Inc.	BOLD	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1666306	Arch Venture Fund Ix, L.p.	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	No	No
1666307	Arch Venture Fund Ix Overage, L.p.	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	No	No
1723172	Arch Venture Partners Ix Overage, L.p.	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	No	No
1723173	Arch Venture Partners Ix, L.p.	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	No	No
1723174	Arch Venture Partners Ix, Llc	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	No	No
1757017	Arch Venture Fund X Overage, L.p.	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	No	No
1768905	Arch Venture Partners X Overage, L.p.	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	No	No
1769012	Arch Venture Partners X, Llc	8755 West Higgins Road, Suite 1025 Chicago IL 60631	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-04-02	589,743	$0.00	617,092	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2024-04-02	787,545	$0.00	828,570	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2024-04-02	1,048,433	$0.00	1,048,433	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2024-04-02	66,667	$16.00	683,759	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2024-04-02	133,333	$16.00	1,181,766	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2024-04-02	424,908	$0.00	424,908	$0.00
Common Stock	Series A Convertible Preferred Stock	Disposition	2024-04-02	586,080	$0.00	586,080	$0.00
Common Stock	Series A Convertible Preferred Stock	Disposition	2024-04-02	454,212	$0.00	454,212	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2024-04-02	227,920	$0.00	227,920	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2024-04-02	164,835	$0.00	164,835	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2024-04-02	201,465	$0.00	201,465	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2024-04-02	366,301	$0.00	366,301	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.
Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage.
ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any.
Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any.
Represents shares purchased by ARCH IX in the Issuer's initial public offering.
Represents shares purchased by ARCH X Overage in the Issuer's initial public offering.